Urokinase-Type Plasminogen Activator
-
Subject Areas on Research
-
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia.
-
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
-
Acute management of intracranial hemorrhage in patients receiving thrombolytic therapy: case reports.
-
Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy.
-
Adoption of thrombolytic therapy in the management of acute myocardial infarction.
-
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
-
Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.
-
Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute myocardial infarction. TAMI Study Group.
-
Burn Injury Alters Epidermal Cholinergic Mediators and Increases HMGB1 and Caspase 3 in Autologous Donor Skin and Burn Margin.
-
Calcium modulates the expression of urokinase plasminogen activator and plasminogen activator inhibitor 2 by human keratinocytes.
-
Catabolism of human tissue plasminogen activator in mice.
-
Catheter-related sepsis refractory to antibiotics treated successfully with adjunctive urokinase infusion.
-
Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction.
-
Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor.
-
Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
-
Co-expression of urokinase with haptoglobin in human carcinomas.
-
Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.
-
Comparison of plasminogen binding and activation on extracellular matrices produced by vascular smooth muscle and endothelial cells.
-
Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis.
-
Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group.
-
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
-
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
-
Coronary bypass surgery improves global and regional left ventricular function following thrombolytic therapy for acute myocardial infarction. TAMI Study Group.
-
Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group.
-
Differential mechanisms of failure of autogenous and non-autogenous bypass conduits: an assessment following successful graft thrombolysis.
-
Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
-
Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review.
-
Embolization of cardiac mural thrombus: complication of intraarterial fibrinolysis.
-
Epidermal plasminogen activator is abnormal in cutaneous lesions.
-
Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.
-
Expression of plasminogen activator enzymes in psoriatic epidermis.
-
Expression of plasminogen activators in basal cell carcinoma.
-
Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis.
-
Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty.
-
Human epidermal plasminogen activator. Characterization, localization, and modulation.
-
Hyaluronan fragments induce plasminogen activator inhibitor-1 and inhibit urokinase activity in mouse alveolar macrophages: a potential mechanism for impaired fibrinolytic activity in acute lung injury.
-
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
-
Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction.
-
Indices of reperfusion in patients with acute myocardial infarction using characteristics of the CK-MB time-activity curve.
-
Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
-
Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1).
-
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
-
Keratinocyte urokinase-type plasminogen activator is secreted as a single chain precursor.
-
Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.
-
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group.
-
Lipoprotein (a) regulates plasmin generation and inhibition.
-
Management of infrainguinal occluded vein bypasses with a combined approach of thrombolysis and surveillance. A prospective study.
-
Mechanical versus chemical thrombolysis: an in vitro differentiation of thrombolytic mechanisms.
-
Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
-
Migrating keratinocytes express urokinase-type plasminogen activator.
-
Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.
-
Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
-
Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
-
New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes.
-
Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction.
-
Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
-
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
-
Percutaneous transhepatic recanalization and thrombolysis of the superior mesenteric vein.
-
Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy.
-
Plasminogen acceleration of urokinase thrombolysis.
-
Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits.
-
Primary upper-extremity deep venous thrombosis.
-
Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction.
-
Provocative angiography in patients with gastrointestinal hemorrhage of obscure origin.
-
Purification and characterization of a fibrinolytic enzyme of Bacillus subtilis DC33, isolated from Chinese traditional Douchi.
-
Rapid visualization of massive pulmonary emboli utilizing intravascular ultrasound.
-
Ratio of ST-segment and myoglobin slopes to estimate myocardial salvage during thrombolytic therapy for acute myocardial infarction.
-
Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings.
-
Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages.
-
Results of high dose intravenous urokinase for acute myocardial infarction.
-
Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model.
-
SAMP14, a novel, acrosomal membrane-associated, glycosylphosphatidylinositol-anchored member of the Ly-6/urokinase-type plasminogen activator receptor superfamily with a role in sperm-egg interaction.
-
Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts.
-
Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
-
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
-
Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty.
-
Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
-
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
-
Soluble Urokinase Receptor and Acute Kidney Injury.
-
Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
-
Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin.
-
Studies on the medical treatment of deep vein thrombosis.
-
THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
-
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
-
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
-
The effect of divalent cations on the conformation and function of human plasminogen.
-
The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis.
-
The importance of the preactivation peptide in the two-stage mechanism of human plasminogen activation.
-
The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
-
Thrombolysis in acute peripheral arterial occlusion: predictors of immediate success.
-
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
-
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
-
Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells.
-
Treatment of dural sinus thrombosis by urokinase infusion.
-
Two urokinase dose regimens in native arterial and graft occlusions: initial results of a prospective, randomized clinical trial.
-
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
-
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
-
Urokinase treatment of neonatal aortoiliac thrombosis caused by umbilical artery catheterization: a case report.
-
Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. The TAMI Study Group.
-
mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis.
-
Keywords of People